| Ticker | ALXO |
|---|---|
| ISIN | US00166B1052 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | 88.932.593 € |
| Beta | 0,5 |
| Sitio web | https://www.alxoncology.com |
| CEO | Jason W. Lettmann |
| Fecha de IPO | 17/07/2020 |
| País | US |
| Dirección | 323 Allerton Avenue, South San Francisco, CA, 94080 |
| Volumen | 758.236 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor recepto...
El precio actual de ALX Oncology Holdings Inc. (ALXO) es de 1,58 , con una variación del -3,66%.
ALX Oncology Holdings Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones